Back to Search Start Over

Surgical strategy for inflammatory thoracic aortic aneurysms in the endovascular surgery era.

Authors :
Oishi, Kiyotoshi
Mizuno, Tomohiro
Fujiwara, Tatsuki
Kuroki, Hidehito
Yashima, Masafumi
Takeshita, Masashi
Nagaoka, Eiki
Oi, Keiji
Arai, Hirokuni
Source :
Journal of Vascular Surgery; Jan2022, Vol. 75 Issue 1, p74-74, 1p
Publication Year :
2022

Abstract

Inflammatory thoracic aortic aneurysms (TAAs) are very rare aortic conditions. Resection and replacement of the inflammatory aorta is the first-line treatment, and thoracic endovascular aortic repair (TEVAR) has recently been reported as a less invasive alternative even for this aortic cohort. In the present study, we reviewed our experience with inflammatory TAAs and assessed the preoperative management, surgical procedures, and outcomes. From 2006 to 2019, 21 surgeries were performed for inflammatory TAAs in 17 of 2583 patients (0.7%) who had undergone cardiovascular surgery at our institution. The etiologies were Takayasu's arteritis in 13 patients, giant cell arteritis in 2, antineutrophil cytoplasmic antibody-associated vasculitis in 1, and unknown in 1. The mean follow-up period was 66.2 ± 50.2 months (range, 19–186 months). Three patients had undergone multiple surgeries. The aorta was replaced in 14 patients (ascending aorta in 9, aortic arch in 4, and thoracoabdominal aorta in 1). Three isolated TEVARs were performed in two patients and single-stage hybrid aortic repair (ascending aorta and partial arch replacement combined with zone 0 TEVAR) in four patients for extended arch and descending thoracic aortic aneurysms. Stent grafts were deployed on the native aorta in five of the seven TEVARs. The perioperative inflammation was well-controlled with prednisolone (mean dose, 7.4 ± 9.4 mg) in all patients except for one who had required two surgeries under inflammation-uncontrolled situations. No aorta-related complications, including anastomotic aneurysms and TEVAR-related aortic dissection, developed during the follow-up period, and the 5-year freedom from all-cause death was 92.9%. The mid-term outcomes of surgery for inflammatory TAAs were acceptable. Although replacement remains the standard procedure for inflammatory TAAs, TEVAR is a less invasive acceptable alternative when the inflammation is properly managed. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
07415214
Volume :
75
Issue :
1
Database :
Supplemental Index
Journal :
Journal of Vascular Surgery
Publication Type :
Academic Journal
Accession number :
154142139
Full Text :
https://doi.org/10.1016/j.jvs.2021.06.479